Log in

Catalent Stock Forecast, Price & News

+0.68 (+0.80 %)
(As of 09/21/2020 12:00 AM ET)
Today's Range
Now: $85.55
50-Day Range
MA: $86.63
52-Week Range
Now: $85.55
Volume1.89 million shs
Average Volume1.44 million shs
Market Capitalization$14.04 billion
P/E Ratio77.07
Dividend YieldN/A
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics and Specialty Drug Delivery segment formulates, develops, and manufactures small molecule and biologic drug products in prefilled syringes, vials and cartridges, blow-fill-seal unit doses, and injectable formats; develops biologic cell lines; manufactures biologic drug substances; and offers bioanalytical development and testing services. The Oral Drug Delivery segment formulates, develops, and manufactures oral dosage forms using proprietary and conventional drug delivery technologies, such as Zydis, OptiDose CR, OptiPact, OptiForm API and Solution Suite, Pharmatek SD Spray Drying, OptiMelt hot melt extrusion, Micron particle size reduction, and FlexDose; and provides stick pack formulation and filling, and analytical development and testing services. The Clinical Supply Services segment offers Manufacturing, packaging, labeling, storage, distribution, and inventory management for drugs and biologics clinical trials; FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Read More
Catalent logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.27 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$3.09 billion
Cash Flow$3.78 per share
Book Value$18.71 per share


Net Income$173 million


Market Cap$14.04 billion
Next Earnings Date11/3/2020 (Estimated)
+0.68 (+0.80 %)
(As of 09/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CTLT News and Ratings via Email

Sign-up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Catalent (NYSE:CTLT) Frequently Asked Questions

How has Catalent's stock been impacted by COVID-19?

Catalent's stock was trading at $46.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CTLT stock has increased by 85.8% and is now trading at $85.55.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Catalent?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Catalent

When is Catalent's next earnings date?

Catalent is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Catalent

How were Catalent's earnings last quarter?

Catalent Inc (NYSE:CTLT) announced its earnings results on Monday, August, 31st. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.11. The business earned $947.60 million during the quarter, compared to the consensus estimate of $943.62 million. Catalent had a return on equity of 14.88% and a net margin of 7.13%. The business's revenue for the quarter was up 30.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.70 earnings per share.
View Catalent's earnings history

What guidance has Catalent issued on next quarter's earnings?

Catalent issued an update on its FY 2021 Pre-Market earnings guidance on Monday, August, 31st. The company provided earnings per share (EPS) guidance of 2.19-2.42 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.16. The company issued revenue guidance of $3.45-3.6 billion, compared to the consensus revenue estimate of $3.36 billion.

What price target have analysts set for CTLT?

8 equities research analysts have issued 12 month price targets for Catalent's stock. Their forecasts range from $75.00 to $105.00. On average, they anticipate Catalent's share price to reach $94.86 in the next twelve months. This suggests a possible upside of 10.9% from the stock's current price.
View analysts' price targets for Catalent

Who are some of Catalent's key competitors?

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), Home Depot (HD) and AT&T (T).

Who are Catalent's key executives?

Catalent's management team includes the following people:
  • Mr. John R. Chiminski, Chairman & CEO (Age 55)
  • Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 47)
  • Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
  • Mr. Jonathan Arnold, Pres of Oral Drug Delivery Bus. Unit (Age 53)
  • Mr. Alessandro Maselli, Pres & COO (Age 47)

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Who are Catalent's major shareholders?

Catalent's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.78%), Bank of New York Mellon Corp (1.14%), Viking Global Investors LP (0.96%), Thrivent Financial for Lutherans (0.96%), GW&K Investment Management LLC (0.79%) and Federated Hermes Inc. (0.78%). Company insiders that own Catalent stock include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, Donald E Morel, Jr, Gregory T Lucier, John J Greisch, John R Chiminski, Lance Miyamoto, Michael J Grippo, Peter L Buzy, Ricardo Pravda, Scott Gunther, Steven L Fasman and William Downie.
View institutional ownership trends for Catalent

Which major investors are selling Catalent stock?

CTLT stock was sold by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Viking Global Investors LP, TimesSquare Capital Management LLC, AJO LP, Macquarie Group Ltd., Bernzott Capital Advisors, Bank of America Corp DE, and Thrivent Financial for Lutherans. Company insiders that have sold Catalent company stock in the last year include Alessandro Maselli, Aristippos Gennadios, Gregory T Lucier, John R Chiminski, Michael J Grippo, Ricardo Pravda, and Scott Gunther.
View insider buying and selling activity for Catalent

Which major investors are buying Catalent stock?

CTLT stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Sumitomo Mitsui Trust Holdings Inc., Nuveen Asset Management LLC, Vanguard Group Inc., Public Employees Retirement Association of Colorado, Swiss National Bank, Strs Ohio, and Picton Mahoney Asset Management. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, Gregory T Lucier, John J Greisch, and Peter L Buzy.
View insider buying and selling activity for Catalent

How do I buy shares of Catalent?

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $85.55.

How big of a company is Catalent?

Catalent has a market capitalization of $14.04 billion and generates $3.09 billion in revenue each year. The company earns $173 million in net income (profit) each year or $1.88 on an earnings per share basis. Catalent employs 13,900 workers across the globe.

What is Catalent's official website?

The official website for Catalent is www.catalent.com.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.